PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.21%
R&D growth while TRVN reduces spending. John Neff would investigate strategic advantage.
-38.56%
G&A reduction while TRVN shows 19.32% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
-22.93%
Other expenses reduction while TRVN shows 0.00% growth. Joel Greenblatt would examine efficiency.
-7.06%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-7.06%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
-22.93%
D&A reduction while TRVN shows 136.71% growth. Joel Greenblatt would examine efficiency.
7.02%
EBITDA growth below 50% of TRVN's 23.12%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
7.06%
Operating income growth below 50% of TRVN's 22.49%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
148.79%
Other expenses growth while TRVN reduces costs. John Neff would investigate differences.
10.36%
Pre-tax income growth below 50% of TRVN's 21.70%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.36%
Net income growth below 50% of TRVN's 21.70%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
28.30%
EPS growth 1.25-1.5x TRVN's 24.00%. Bruce Berkowitz would examine sustainability.
28.30%
Diluted EPS growth 1.25-1.5x TRVN's 24.00%. Bruce Berkowitz would examine sustainability.
24.68%
Share count reduction below 50% of TRVN's 2.97%. Michael Burry would check for concerns.
24.68%
Diluted share reduction below 50% of TRVN's 2.97%. Michael Burry would check for concerns.